Meeting
2013 ASCO Annual Meeting
NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi).
Authors
Kurt A. Jaeckle
Mayo Clinic, Jacksonville, FL
Kurt A. Jaeckle , David Schiff , S. Keith Anderson , Evanthia Galanis , Philip J. Stella , Patrick J. Flynn , Jann Nagina Sarkaria , Caterina Giannini , Bradley J. Erickson , Jan C Buckner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00329719
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2014)
DOI
10.1200/jco.2013.31.15_suppl.2014
Abstract #
2014
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.
First Author: K. A. Jaeckle
Poster
2020 ASCO Virtual Scientific Program
Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO).
First Author: Mario Caccese
Poster
2020 ASCO Virtual Scientific Program
Association of peripheral blood CD4+ T-cell depletion under temozolomide with inferior survival of patients with IDH wildtype glioblastoma.
First Author: Michael Weller
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih